

LITERATURA

- NAMS Position Statement: The 2022 Hormone Therapy Position Statement. *Menopause*. 2022;29(7):767-94.
- Fait T. Hormone replacement therapy: latest developments and clinical practice. *Drugs in Context*. 2019;8:212551.
- Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management. *Endocrinol Metab Clin North Am*. 2015;44:497-515.
- Biglia N, Cagnacci A, Gambacciani M, et al. Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? *Climacteric* 2017;20(4):306-12.
- Thurston R, Chang Y, Barinas-Mitchel E, et al. Physiologically assessed hot flashes and endothelial function among midlife women. *Menopause*. 2017;24(8):886-93.
- Herber-Gast B, Brown WJ, Mishra GD. Hot flushes and night sweats are associated with coronary heart disease risk in mid-life: a longitudinal study. *BJOG* 2015;122:1560-7.
- Thurston RC, Aizenstein HJ, Derby CA, et al. Menopausal hot flashes and white matter hyperintensities. *Menopause*. 2016;23:27-32.
- Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. *JAMA*. 1998 Aug 19;280(7):605-13. doi: 10.1001/jama.280.7.605. PMID: 9718051.
- Koire A, Joffe H, Buckley R. Replacement in the Prevention and Treatment of Cognitive Decline, Dementia, and Cognitive Dysfunction of Depression. *Harv Rev Psychiatry*. 2022; 30(4):215-22.
- Kim J, Chang JH, Jeong MJ, et al. A systematic review and metaanalysis of effects of menopause hormone therapy on cardiovascular diseases. *Sci Rep*. 2020;10(1):20631.
- Fait T, Vrablik M. Coronary heart disease and hormone replacement therapy – from primary and secondary prevention to the window of opportunity. *Neuro Endocrinol Lett*. 2012;33(Suppl. 2):17-21.
- Fait T. Klíč k nasazení HRT. *Gynek Porod*. 2020;4(3):133-6.
- Panay N, Anderson RA, Nappi RE, et al. Premature ovarian insufficiency: an International Menopause Society White Paper. *Climacteric*. 2020;23(5):426-46.
- Tan DA, Dayu ARB. Menopausal hormone therapy: why we should no longer be afraid of the breast cancer risk. *Climacteric*. 2022;25(4):362-8.
- Ruan X, Mueck AO. Primary choice of estrogen and progestin as components of HRT. *Climacteric*. 2022;25(5):443-52.
- Fournier A, Berino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. *Breast Cancer Res Treat*. 2008;107(1):103-11.
- Fait T. Tibolon – jediný zástupce skupiny STEARs. *Cas Lek Ces*. 2019;158:107-111.
- Scarabin PY, Oger E, Plu-Bureau G; EStrogen and THrombo-Embolic Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. *Lancet*. 2003 Aug 9;362(9382):428-32. doi: 10.1016/S0140-6736(03)14066-4. PMID: 12927428.
- Crandall CJ, Mehta JM, Manson JE. Management of menopausal symptoms: a review. *JAMA*. 2023;329(5):405-20.
- Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. *JAMA*. 2003;290(13):1729-38.
- Robbins JA, Argaki A, Crandall CJ, et al. WHI trials: interaction of calcium and vitamin D with hormone therapy. *Menopause*. 2014;21(2):116-23.
- Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of nonvertebral fracture: a meta-analysis of randomized trials. *JAMA*. 2001;285(22):2891-7.
- Zhu L, Jiang X, Sun Y, et al. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. *Menopause*. 2016;23(4):461-70.
- NAMS Management of symptomatic vulvovaginal atrophy, position statement of the North American Menopause Society. *Menopause*. 2013;20:888-902.
- Ulrich LSG, Naessen T, Elia D, et al. Endometrial safety of ultra-low-dose Vagifem 10 µg in postmenopausal women with vaginal atrophy. *Climacteric* 2010;1:228-237.
- Sirotkin AV, Harrath AH. Phytoestrogens and their effects. *Eur J Pharmacol*. 2014;741:230-6.
- Duncan AM, Phipps WR, Kurzer MS. Phyto-estrogens. *Best Practice Research Clin Endocrin Metab*. 2003;17(2):253-71.
- Ye YB, Tang XY, Verbruggen M, Su YX. Soy isoflavones attenuate bone loss in early postmenopausal Chinese women. *Eur J Nutr*. 2006;3:1-8.
- Atkinson C, Newton KM, Bowless EJ, et al. Demographic, anthropometric, and lifestyle factors and dietary intakes in relation to daidzein-metabolizing phenotypes among premenopausal women in USA. *Am J Clin Nutr*. 2008;87:679-87.
- Labos G, Trakakis E, Pliatsika P, et al. Efficacy and safety of DT56a (Femarelle) compared to hormone therapy in Greek postmenopausal women. *J Endocrinol Invest*. 2013;36:521-6.
- Sánchez-Borrego R, Mendoza N, Llana P. A prospective study of DT56a (Femarelle®) for the treatment of menopause symptoms. *Climacteric*. 2015;10:1-8.
- Fait T, Borovsky M. DT56a in treatment of climacteric syndrome in a Central European population sample. *Bratislava Medical Journal*. 2021;122(5):301-4.
- Hellström AC, Muntzing J. The pollen extract Femal – a nonestrogenic alternative to hormone therapy in women with menopausal symptoms. *Menopause*. 2012;19(7):825-9.
- Fait T, Sailer M, Regidor PA. Prospective observational study to evaluate the efficacy and safety of the pollen extract Séréllys® in the management of women with menopausal symptoms. *Gynecol Endocrinol*. 2019;35(4):360-3.
- Llana P, Garcia-Portilla P, Llana P, Suarez D, et al. Depressive disorders and the menopause transition. *Maturitas*. 2012;71:120-30.
- Toffol E, Kekiheimo O, Patronen T. Hormone therapy and mood in in perimenopausal women. *Menopause*. 2015;22(5):564-78.
- Liu T, Chen S, Milke GI, et al. Effects of exercise on vasomotor symptoms in menopausal women: a systematic review and meta-analysis. *Climacteric*. 2022;29:1-10.

Připravujeme do příští Medicíny pro praxi

4

- **Přehledové články**
 - Revmatoidní artritida – diagnostika a léčba
 - Celiakie v dnešní době
- **Mezioborové přehledy**
 - Pohled na užívání ACE inhibitorů + sartanu – diabetická nefropatie – kdy použít
 - Spolupráce poskytovatele zdravotnické záchrané služby a ambulantního sektoru
- **Farmakoterapie aktuálně**
 - Psychohygienu praktického lékaře
- **Pro sestry**
 - Perkutánní endoskopická gastrostomie, jejunostomie (PEG, PEJ) v domácím ošetření z pohledu sestry
- **Nejčastější omyly v diagnostice**
 - Diabetologie – úskalí diagnózy cukrovky, rozlišení typů
- a mnoho dalších...

▼
VYJDE
V ZÁŘÍ

SOLEN
MEDICAL EDUCATION